CN109862888B - 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 - Google Patents

用于治疗非酒精性脂肪性肝炎的方法和药物组合物 Download PDF

Info

Publication number
CN109862888B
CN109862888B CN201780065451.5A CN201780065451A CN109862888B CN 109862888 B CN109862888 B CN 109862888B CN 201780065451 A CN201780065451 A CN 201780065451A CN 109862888 B CN109862888 B CN 109862888B
Authority
CN
China
Prior art keywords
ubenimex
administered
inhibitor
nash
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780065451.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109862888A (zh
Inventor
熊晓峰
大卫·A·克里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of CN109862888A publication Critical patent/CN109862888A/zh
Application granted granted Critical
Publication of CN109862888B publication Critical patent/CN109862888B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780065451.5A 2016-09-28 2017-09-28 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 Active CN109862888B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662400963P 2016-09-28 2016-09-28
US62/400,963 2016-09-28
US201762460606P 2017-02-17 2017-02-17
US62/460,606 2017-02-17
US201762469722P 2017-03-10 2017-03-10
US62/469,722 2017-03-10
PCT/US2017/054087 WO2018064373A1 (en) 2016-09-28 2017-09-28 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
CN109862888A CN109862888A (zh) 2019-06-07
CN109862888B true CN109862888B (zh) 2022-08-12

Family

ID=61760848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780065451.5A Active CN109862888B (zh) 2016-09-28 2017-09-28 用于治疗非酒精性脂肪性肝炎的方法和药物组合物

Country Status (6)

Country Link
US (2) US10588880B2 (https=)
EP (1) EP3518918A4 (https=)
JP (1) JP7022136B2 (https=)
KR (1) KR102399254B1 (https=)
CN (1) CN109862888B (https=)
WO (1) WO2018064373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
CA3101274A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3811937A1 (en) * 2019-10-24 2021-04-28 Sorbonne Universite Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245813B1 (en) * 1995-06-21 2001-06-12 Sichuan Industrial Institute Of Antibiotics Use of ubenimex and the pharmaceutical composition containing it for treating virus hepatitis
CN101415422A (zh) * 2006-02-09 2009-04-22 第一三共株式会社 抗癌药用组合物
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
CN105848718A (zh) * 2013-12-04 2016-08-10 盖尔梅德研究与发展有限公司 Aramchol盐
CN105848652A (zh) * 2013-10-22 2016-08-10 史蒂文·霍夫曼 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052449A (en) 1974-07-01 1977-10-04 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
JPH0759507B2 (ja) * 1989-02-23 1995-06-28 日本化薬株式会社 骨髄異形成症候群治療剤
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
JP2009109426A (ja) * 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
WO2012071459A1 (en) 2010-11-22 2012-05-31 The Regents Of The University Of California New indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US9233089B2 (en) 2012-03-23 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
CN104902921A (zh) * 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
DK3043865T3 (da) * 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104784178B (zh) * 2015-05-08 2017-04-12 重庆医科大学 尼克酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
EP3716975A4 (en) 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245813B1 (en) * 1995-06-21 2001-06-12 Sichuan Industrial Institute Of Antibiotics Use of ubenimex and the pharmaceutical composition containing it for treating virus hepatitis
CN101415422A (zh) * 2006-02-09 2009-04-22 第一三共株式会社 抗癌药用组合物
CN105848652A (zh) * 2013-10-22 2016-08-10 史蒂文·霍夫曼 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
CN105848718A (zh) * 2013-12-04 2016-08-10 盖尔梅德研究与发展有限公司 Aramchol盐
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma;Masafumi Yamashita 等;《Int J Oncol》;20160425;第49卷(第1期);第89-98页 *
The effects of bestatin, a microbial aminopeptidase inhibitor, on epidermal growth factor-induced DNA synthesis and cell division in primary cultured hepatocytes of rats;S Takahashi 等;《Exp Cell Res》;19890801;第183卷(第2期);第399-412页 *
乌苯美司抗癌作用的研究进展;胡承波 等;《中国药房》;20130828;第24卷(第32期);第3061-3063页 *
乌苯美司抗鸭乙型肝炎病毒的实验研究;陈压西 等;《中华肝脏病杂志》;19980320;第6卷(第1期);第14-15页+第25页 *
慢性病毒性肝炎与非酒精性脂肪性肝病;彭劼 等;《第二届广东省脂肪肝专题研讨会论文汇编》;20111224;第34-40页 *
法尼酯衍生物X 受体在慢性肝病中的作用及机制研究进展;许文萱 等;《中国药理学通报》;20160226;第32卷(第3期);第314-319页 *

Also Published As

Publication number Publication date
JP7022136B2 (ja) 2022-02-17
CN109862888A (zh) 2019-06-07
US20190307714A1 (en) 2019-10-10
JP2019529566A (ja) 2019-10-17
US10588880B2 (en) 2020-03-17
WO2018064373A1 (en) 2018-04-05
US20200237696A1 (en) 2020-07-30
EP3518918A4 (en) 2020-04-22
KR20190058532A (ko) 2019-05-29
EP3518918A1 (en) 2019-08-07
US11571403B2 (en) 2023-02-07
KR102399254B1 (ko) 2022-05-17

Similar Documents

Publication Publication Date Title
CN109862888B (zh) 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
AU2013259526B2 (en) New methods
US10449154B2 (en) Treatment of NASH with Gemcabene
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
ES3026786T3 (en) Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
KR20230015884A (ko) 비알코올성 지방간염 치료를 위한 세마글루타이드
Kojecky et al. A single or split dose picosulphate/magnesium citrate before colonoscopy: comparison regarding tolerance and efficacy with polyethylene glycol. A randomized trial.
CN111093705A (zh) 包含fxr激动剂的组合
TW201811372A (zh) 利用fxr促效劑之方法
AU2018375298A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
BRPI0707670A2 (pt) composiÇço farmacÊutica, e, uso de um composto meglitinida
US20120108528A1 (en) New therapeutic approaches for treating neuroinflammatory conditions
CN115715192A (zh) 用于治疗或预防血液系统异常和/或相关疾病的包含15-hepe的组合物
JP2019038858A (ja) ペマフィブラートを含有する医薬
Hirata et al. Evaluation for peritoneal injury at an early stage using dual macromolecular markers
Ha et al. Diabetes & Metabolism Journal
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
HK1256960A1 (en) Treatment of mixed dyslipidemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant